Neuromyelitis Optica Spectrum Disorder: An Early Diagnosis to Prevent Blindness and Paraplegia

被引:0
|
作者
George, Minny [1 ]
Gantioque, Raymund [1 ]
机构
[1] Calif State Univ, Sch Nursing, 5151 State Univ Dr, Los Angeles, CA 90032 USA
来源
JNP- THE JOURNAL FOR NURSE PRACTITIONERS | 2023年 / 19卷 / 07期
关键词
Devic's disease; monoclonal antibodies; neuromyelitis optica; neuromyelitis optica (NMO) antibody AQP4-IgG; neuromyelitis optica spectrum disorder; optic neuritis; transverse myelitis; MULTICENTER; EFFICACY; SAFETY; TRIAL;
D O I
10.1016/j.nurpra.2023.104654
中图分类号
R47 [护理学];
学科分类号
1011 ;
摘要
Neuromyelitis optica spectrum disorder (NMOSD), also referred to as Devic's disease, is a rare autoimmune disease of the central nervous system that primarily affects both the optic nerve (optic neuritis) and the spinal cord (myelitis). Patients presenting solely with optic neuritis or transverse myelitis can make diagnosis difficult. If left untreated, it may result in blindness and paralysis. Early and accurate diagnosis is crucial for treating and preventing further NMOSD attacks. This article describes the case of a previously healthy patient who presented with NMOSD. In addition, the clinical presentation, diagnostics, and treatment methods are discussed.& COPY; 2023 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页数:4
相关论文
共 50 条
  • [21] Patients with Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder: Turkish Multicenter Data
    Altintas, A.
    Karabudak, R.
    Balci, B. Petek
    Terzi, M.
    Soysal, A.
    Saip, S.
    Kurne, A. Tuncer
    Uygunoglu, U.
    Nalbantoglu, M.
    Gozubatik-Celik, G.
    Isik, N.
    Celik, Y.
    Gokcay, F.
    Duman, T.
    Boz, C.
    Yucesan, C.
    Celebisoy, N.
    Diker, S.
    Isikay, I. C.
    Kansu, T.
    Siva, A.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 (06) : 824 - 825
  • [22] Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset
    Collongues, N.
    Marignier, R.
    Jacob, A.
    Leite, M. I.
    Sivas, A.
    Paul, F.
    Zephir, H.
    Akman-Demirs, G.
    Elsone, L.
    Jarius, S.
    Papeix, C.
    Mutch, K.
    Saips, S.
    Wildemann, B.
    Kitley, J.
    Karabudak, R.
    Aktas, O.
    Kuscu, D.
    Altintas, A.
    Palace, J.
    Confavreux, C.
    De Seze, J.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (08) : 1086 - 1094
  • [23] Early MRI changes of neuromyelitis optica spectrum disorder in patients of Uzbekistan
    Shokhimardonov, S.
    Khudjanov, S.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
  • [24] Early indicators of relapses vs pseudorelapses in neuromyelitis optica spectrum disorder
    Kessler, Remi A.
    Mealy, Maureen A.
    Levy, Michael
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2016, 3 (05):
  • [25] Early Predictors of Relapses versus Pseudorelapses in Neuromyelitis Optica Spectrum Disorder
    Kessler, Remi
    Mealy, Maureen
    Levy, Michael
    NEUROLOGY, 2016, 86
  • [26] Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder
    Fung, Simon
    Shirley, Matt
    CNS DRUGS, 2023, 37 (04) : 363 - 370
  • [27] Inebilizumab for treatment of neuromyelitis optica spectrum disorder
    Tullman, Mark J.
    Zabeti, Aram
    Vuocolo, Scott
    Dinh, Quinn
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2021, 11 (05) : 341 - 352
  • [28] Pregnancy outcomes in neuromyelitis optica spectrum disorder
    Vishnevetsky, A.
    Levy, M.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 140 - 140
  • [29] Satralizumab in the treatment of neuromyelitis optica spectrum disorder
    Duchow, Ankelien
    Bellmann-Strobl, Judith
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2021, 11 (01) : 49 - 59
  • [30] Cyclophosphamide treatment in Neuromyelitis Optica Spectrum Disorder
    Gulluoglu, H.
    Uysal, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 798 - 798